返回 
加入收藏
美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎（UC）的临床疗效及安全性。方法：选取2012年3月－2014年8月在我院消化内科治疗的活动期UC患者120例，按照随机数字表法分为观察组和对照组，各60例。两组患者均给予活动期UC常规治疗，对照组患者在此基础上口服美沙拉嗪肠溶片1 g，tid；观察组患者在对照组的基础上加用康复新液30 mL加入生理盐水150 mL稀释后灌肠，qd。两组患者均治疗30 d。观察两组患者治疗前后血清肿瘤坏死因子（TNF）-α、白细胞介素1（IL-1）、IL-8、IL-10、超氧化物歧化酶（SOD）、一氧化氮（NO）、过氧化脂质（LPO）水平，比较两组患者临床疗效、复发率、肠镜疗效及不良反应发生情况。 结果：治疗前，两组患者血清TNF-α、IL-1、IL-8、IL-10、SOD、NO、LPO水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血清TNF-α、IL-1、IL-8、NO、LPO水平均明显降低，血清IL-10、SOD水平明显升高；且观察组患者血清TNF-α、IL-1、IL-8、NO、LPO水平明显低于对照组， IL-10、SOD水平明显高于对照组，差异均有统计学意义（P＜0.05）。观察组患者临床有效率为83.3％，复发率为11.7％，肠镜有效率为88.3％，显著优于对照组的66.7％、30.0％、70.0％，差异均有统计学意义（P＜0.05）。两组患者总不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：美沙拉嗪联合康复新液保留灌肠可有效减轻活动期UC患者炎症反应及氧自由基损伤，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of mesalazine combined with Kangfuxin solution retention enema in the treatment of active ulcerative colitis （UC）. METHODS： A total of 120 patients diagnosed as active UC selected from gastroenterology department of our hospital during Mar. 2012 to Aug. 2014 were divided into observation group and control group according to random number table， with 60 cases in each group. Both groups received conventional treatment of active UC. Control group was additionally given Mesalazine enteric coated tablets 1 g， tid， on the basis of routine treatment. Observation group was additionally given Kangfuxin solution 30 mL diluted with normal saline 150 mL for enema， qd， on the basis of control group. Both groups were treated for 30 d. The serum levels of TNF-α， IL-1， IL-8， IL-10， SOD， NO and LPO were observed in 2 groups before and after treatment； clinical efficacies， recurrence rates， colonoscopy efficacies and the occurrence of ADR were compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in the serum levels of TNF-α， IL-1， IL-8， IL-10， SOD， NO or LPO between 2 groups （P＞0.05）. After treatment， the serum levels of TNF-α， IL-1， IL-8， NO and LPO in 2 groups were decreased significantly， while the serum levels of IL-10 and SOD were increased significantly； the serum levels of TNF-α， IL-1， IL-8， NO and LPO in observation group were significantly lower than control group， while the serum levels of IL-10 and SOD were significantly higher than control group， with statistical significance （P＜0.05）. Clinical response rate， recurrence rate and colonoscopy response rate of observation group were 83.3％， 11.7％ and 88.3％， which were significantly better than 66.7％， 30.0％， 70.0％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Mesalazine combined with Kangfuxin solution can effectively alleviate inflammatory reaction in patients with active UC， and reduce oxygen free radical damage with good safety. |
| 期刊： | 2017年第28卷第29期 |
| 作者： | 何元清，何子彬，张晗，何丽，杨涛，赵娟，王玉琼，周骥 |
| AUTHORS： | HE Yuanqing，HE Zibin，ZHANG Han，HE Li，YANG Tao，ZHAO Juan，WANG Yuqiong，ZHOU Ji |
| 关键字： | 美沙拉嗪；康复新液；活动期；溃疡性结肠炎；炎症反应 |
| KEYWORDS： | Mesalazine； Kangfuxin solution； Active stage； Ulcerative colitis； Inflammatory reaction |
| 阅读数： | 753 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
